Modification of serum IGF-I, IGFBPs and SHBG levels by different HRT regimens.
Maturitas
; 45(4): 283-91, 2003 Aug 20.
Article
em En
| MEDLINE
| ID: mdl-12927315
ABSTRACT
UNLABELLED During the menopause, levels of SHBG, IGF-I and IGFBPs are significantly modified by the use of different HRT regimens. OBJECTIVE:
The aim of this study is to evaluate the influence of three different HRT regimens on serum levels of SHBG, IGF-I, IGFBP-1 and IGFBP-3 in postmenopausal women.METHODS:
41 postmenopausal women requesting HRT were enrolled in the study. Subjects were divided in three groups according to the therapy assigned; Group A estradiol 2 mg/day+cyproterone acetate 1 mg/day in a cyclic sequential regimen; Group B estradiol hemihydrate 2 mg/day plus norethisterone acetate (NETA) 1 mg/day in a continuous combined regimen; Group C estradiol hemihydrate 1 mg/day plus NETA 0.5 mg/day in a continuous combined regimen. Blood samples were drawn before the start of hormonal treatment and after 6 months of HRT. Levels of SHBG, IGF-I, IGFBP-1 and IGFBP-3 in the serum were measured by means of a specific immunoassay.RESULTS:
In group A, a significant increase of SHBG, no change of IGFBPs and a significant decrease of IGF-I were observed; in group B and in group C, no significant variations for any of the parameters were recorded.CONCLUSIONS:
The association of cyproterone acetate to oral estradiol determines a significant reduction of IGF-I levels and an increase of SHBG; nevertheless, it does not seem to influence the serum levels of the IGF-I binding proteins. The treatment with oral continuous combined estrogens plus androgenic progestins, at low doses, produces minor, not significant, changes in the circulating levels of IGF-I, SHBG and IGFBPs.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Proteínas Sanguíneas
/
Terapia de Reposição de Estrogênios
/
Noretindrona
Idioma:
En
Ano de publicação:
2003
Tipo de documento:
Article